In conclusion, AnxA1 level at admission was significantly higher in patients with CAP with higher severity scores, and was unrelated to CAP etiology; moreover, an elevated AnxA1 level strongly predicted SCAP in patients with CAP. This evidence concerns the gene ANXA1 and syringocystadenoma papilliferum.